- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 126
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more
Clinical trials in Aurora, Colorado
This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Aurora
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Prostate Cancer
- Interventions
- enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 46
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Type 1 Diabetes
- Interventions
- High Dose SAB-142, Low Dose SAB-142, Placebo
- Drug · Other
- Lead sponsor
- SAb Biotherapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- San Francisco, California • San Jose, California • Aurora, Colorado + 19 more
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
- Interventions
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Drug
- Lead sponsor
- Accent Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more
- Conditions
- Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
- Interventions
- Somatropin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more
- Conditions
- Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
- Interventions
- Flow diversion
- Device
- Lead sponsor
- phenox Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Luveltamab tazevibulin
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 1 Day to 12 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Interventions
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Months
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, MRI contrast-enhancing preparations
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 34
- States / cities
- Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more
- Conditions
- Higher-risk Myelodysplastic Syndrome
- Interventions
- Lisaftoclax (APG-2575), Azacitidine Injection, Placebo
- Drug · Other
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more